1. 1) Sasagawa I., Hosoya O., Juni K., Oshima S., Yasuno N., Ohta S., J.J.S.P.C., 19, 544-545 (2012).
2. 2) Ministry of Health, Labour and Welfare. “Guideline for Bioequivalence Studies of Generic Products for Topical Use,” 24 November, 2006: 〈http://www.nihs.go.jp/drug/be-guide/GL061124_hifu.pdf〉, National Institute of Health Sciences Web, cited 17 November, 2014.
3. 3) Ministry of Health, Labour and Welfare. “Guideline for Bioequivalence Studies for Different Topical Dosage Forms,” 24 November, 2006: 〈http://www.nihs.go.jp/drug/be-guide/GL061124_hifu_zaikei.pdf〉, National Institute of Health Sciences Web, cited 17 November, 2014.
4. 4) Ministry of Health, Labour and Welfare. “Guideline for Bioequivalence Studies for Formulation Changes of Topical Dosage Forms,” 1 November, 2010: 〈http://www.nihs.go.jp/drug/be-guide/GL101101_hifu_shohou.pdf〉, National Institute of Health Sciences Web, cited 17 November, 2014.
5. 5) Samaras E. G., Riviere J. E., Ghafourian T., Int. J. Pharm., 434, 280-291 (2012).